Optiver Holding B.V. Makes New Investment in Genmab A/S (NASDAQ:GMAB)

Optiver Holding B.V. purchased a new position in Genmab A/S (NASDAQ:GMAB) in the 4th quarter, HoldingsChannel reports. The fund purchased 36,260 shares of the company’s stock, valued at approximately $757,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. EverSource Wealth Advisors LLC raised its position in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares in the last quarter. Lindbrook Capital LLC increased its position in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC increased its holdings in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after purchasing an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC increased its holdings in shares of Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Trading Up 0.2 %

NASDAQ GMAB opened at $20.63 on Tuesday. The company’s fifty day simple moving average is $20.45 and its 200-day simple moving average is $21.00. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $30.41. The stock has a market cap of $13.66 billion, a P/E ratio of 11.86, a PEG ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, research analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on GMAB. Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. HC Wainwright restated a “buy” rating and issued a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Truist Financial reduced their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and an average target price of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.